Abrocitinib Long-Term Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study

被引：0
|
作者：
Reich, Kristian [1 ]
Silverberg, Jonathan I. [2 ]
de Bruin-Weller, Marjolein [3 ]
Deleuran, Mette [4 ]
Beck, Lisa A. [5 ]
Papp, Kim [6 ]
Farooqui, Saleem A. [7 ]
Zhang, Fan [8 ]
Feeney, Claire [9 ]
Koppensteiner, Herwig [10 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA
[3] Univ Med Ctr Utrecht, Utrecht, Netherlands
[4] Aarhus Univ Hosp, Aarhus, Denmark
[5] Univ Rochester, Med Ctr, Rochester, NY USA
[6] Papp Clin Res & Prob Med Res, Waterloo, ON, Canada
[7] Pfizer R&D UK Ltd, Sandwich, Kent, England
[8] Pfizer Inc, Groton, CT USA
[9] Pfizer Ltd, Tadworth, Surrey, England
[10] Pfizer Corp Austria GmbH, Vienna, Austria
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
44042
引用
收藏
页码：AB116 / AB116
页数：1
相关论文
共 50 条
  • [21] Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension trial up to 172 weeks
    Beck, L.
    Deleuran, M.
    Blauvelt, A.
    Thyssen, J.
    Bissonnette, R.
    de Bruin-Weller, M.
    Chen, Z.
    Levit, N.
    Rodriguez Marco, A.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 11 - 12
  • [22] Long-term dupilumab treatment up to 100 weeks has no impact on serum lipids in patients with moderate-to-severe atopic dermatitis
    Wollenberg, A.
    Bieber, T.
    Khokhar, F. A.
    Chen, Z.
    Shumel, B.
    Rossi, A. B.
    ALLERGY, 2020, 75 : 192 - 193
  • [23] Long-term dupilumab treatment up to 100 weeks reduces serum biomarkers in adult patients with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Thaci, D.
    Bissonnette, R.
    Deleuran, M.
    Bastian, M.
    Harel, S.
    Chen, Z.
    Levit, N. A.
    Rossi, A. B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 55 - 56
  • [24] Long-term dupilumab treatment up to 100 weeks reduces serum biomarkers in adult patients with moderate-to-severe atopic dermatitis
    Thaci, D.
    Bissonnette, R.
    Deleuran, M.
    Harel, S.
    Chen, Z.
    Levit, N. A.
    Rossi, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E122 - E122
  • [25] Long-term efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis who had failed or were intolerant to oral nonsteroidal immunosuppressants: pooled analysis of JADE clinical trials
    Ardern-Jones, M.
    Ameen, M.
    de Bruin-Weller, M.
    Simpson, E.
    Chiu, W. S.
    Biswas, P.
    Chan, G.
    Koulias, C.
    Weidinger, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E151 - E152
  • [26] Long-term safety and efficacy of open-label dupilumab in patients with moderate-to-severe atopic dermatitis
    Deleuran, M.
    Thaci, D.
    Beck, L.
    Forman, S.
    Soong, W.
    Hussain, I.
    Bissonnette, R.
    Bouaziz, J.
    Gelfand, J.
    Lawrence, S.
    Chen, Z.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Graham, N.
    Ardeleanu, M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 34 - 34
  • [27] Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    Forman, Seth
    Soong, Weily
    Hussain, Iftikhar
    Bissonnette, Robert
    Bouaziz, Jean-David
    Gelfand, Joel
    Sher, Lawrence
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB381 - AB381
  • [28] Long-term safety and efficacy of tralokinumab in more than 1400 moderate-to-severe atopic dermatitis patients treated for up to 42 months: An interim analysis of ECZTEND
    Blauvelt, Andrew
    Langley, Richard
    Simpson, Eric
    Warren, Richard B.
    Costanzo, Antonio
    Saeki, Hidehisa
    Toth, Darryl
    Tauber, Marie
    Pinter, Andreas
    Ameen, Mahreen
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB181 - AB181
  • [29] Long-term safety and efficacy of tralokinumab in more than 1400 patients with moderate-to-severe atopic dermatitis treated for up to 42 months: an interim analysis of ECZTEND
    Blauvelt, Andrew
    Langley, Richard
    Simpson, Eric
    Warren, Richard B.
    Costanzo, Antonio
    Saeki, Hidehisa
    Fangel, Stine
    Lassota, Nathan
    Carlsson, Anna
    Toth, Darryl
    Tauber, Marie
    Pinter, Andreas
    Ameen, Mahreen
    Reich, Kristian
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E92 - E93
  • [30] Dupilumab provides long-term efficacy for up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Thyssen, J. P.
    Blauvelt, A.
    Lockshin, B.
    Galus, R.
    Lynde, C.
    Xiao, J.
    Levit, N. A.
    Marco, A. R.
    Shabbir, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E162 - E162
12345